At long last, Roche's anti-PD-L1 Tecentriq was approved on Dec. 6 by the US FDA for use with the company's VEGF inhibitor Avastin and chemotherapy for first-line, metastatic non-squamous, non-small cell lung cancer (NSCLC), though patients with EGFR and ALK mutations were excluded, eliminating an expected labeling advantage.
Approval was supported by the results of the Phase III IMpower150 study, one of eight trials that are part of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?